摘要
目的建立人乳腺癌多药耐药细胞系MCF-7／A，对其生物学特性进行初步分析评价，为后续乳腺癌多药耐药机制研究提供一株较理想的细胞模型。方法以阿霉素（ADM）为诱导药物，人乳腺癌细胞系MCF-7为诱导对象。采用ADM低浓度持续加量诱导方法，建立人乳腺癌多药耐药细胞系MCF-7／A，比较两组细胞形态变化和倍增时间。MTT法测定细胞耐药倍数及多药耐药指数，实时荧光定量PCR检测MDR1、MMP-2、CD44v6mRNA表达水平。结果建成的MCF-7／A耐药细胞株，耐ADM指数为74，撤药培养60d后耐药指数仍维持在50以上，耐药性稳定，并与多种化疗药物有交叉耐药性，MCF-7／A耐药细胞株撤药培养倍增时间较亲本细胞明显缩短，MDR1、MMP-2、CD44v6mRNA表达水平较亲本细胞均有明显增加（均P〈0．01）。结论建立的MCF-7／A模型具有多药耐药细胞的基本生物学特性，可用于乳腺癌多药耐药及侵袭转移机制的研究。
Objective To establish a multi-drug resistant （MDR） breast cancer cell line and to analyze its biologic fea- tures. Methods A multi-drug resistant breast cancer cell line MCF-7/A was established by exposing to adriamycin with step- wise increasing concentration. Its biologic features and drug-resistance were analyzed. The expression of MDR1, MMP-2, CD44v6 mRNAs were detected by real-time PCR. Results A novel adriamycin-resistant breast cancer cell line MCF-7/A was successfully induced, with a resistance index of 74. Comparing with the parental ADR-sensitive cells, MCF-7/A cells presented shorter doubling time, and the expression of MDR1, MMP-2 and CD44v6 mRNAs were significantly up-regulated in MCF-7/A cells. Conclusion A multidrug-resistant cell line MCF-7/A has been established, which can be used to study MDR mechanism of breast cancer cells.
出处
《浙江医学》
CAS
2012年第17期1426-1429,共4页
Zhejiang Medical Journal
基金
杭州市科技发展计划（20090833808）
